Browsing tag:

acute lymphoblastic leukemia


Exciting news was shared in the January 2015 issue of Mycoses, with clinical data revealing that the use of Caspofungin to treat invasive fungal disease in leukemia patients was both positive and responsive. Adult patients who were diagnosed with acute lymphoblastic leukemia attained relief from their suspected fungal disease after the clinical use of Caspofungin.[…]

Read More

Clofarabine, CAS# 123318-82-1, is also known as the brand name Clolar. As an injectable medication used to treat relapsed or refractory acute lymphoblastic leukemia, clofarabine is typically administered after at least two prior regimens. Clofarabine is indicated for the pediatric population, ages 1 to 21 years of age. A common treatment regimen is 52 mg/m2[…]

Read More

The Oncology segment of the pharmaceutical industry is not only a fast growing one, but it is also an area where shortages are anticipated. A decrease in availability of sterile injectable oncology drugs have been reported since 2007.  Furthermore, many of the sterile injectable oncology drugs that experienced shortages in 2010 and 2011 had a[…]

Read More

The latest headline is daunting, with the World Health Organization’s International Agency for Research on Cancer announcing a 75 percent increase in cancer cases worldwide by 2030. This astounding prediction, published in Reuters on June 1, 2012 offered an unfortunate reality, based on data from GLOBOCAN. Causes are thought to be poor lifestyle choices worldwide,[…]

Read More

Local firm supplies active pharmaceutical ingredients to various global pharmaceutical companies who develop new therapies. BOCA RATON, Florida – Promising news for families with children suffering from acute lymphoblastic leukemia, or ALL, was recently published in Reuters Health. Results were released from a study conducted at the University of Colorado School of Medicine and Children’s[…]

Read More

J.R.Stokes Illustrations: Natural Killer: T-cell vs. Leukemia Researchers received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. The group of oncology advisers voted 7-4 endorsing the Vincristine Sulfate CAS# 2068-78-2 liposomal injection, also known as the brand[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service